1. Asano, M., & Takenaka, T. (2010). Drugs for the treatment of urinary disorders associated with prostate hypertrophy-harnal. Laboratory Medicine, 28(18), 3035–3040.
2. Barnes, E. M., Langer, S. Z., & Weiner, N. (1974). Release of norepinephrine and dopamine-β-hydroxylase by nerve stimulation. I. Role of neuronal and extraneuronal uptake and of alpha presynaptic receptors. Journal of Pharmacology and Experimental Therapeutics, 190(3), 431–450.
3. Caine, M., Raz, S., & Zeigler, M. (1975). Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. British Journal of Urology, 47(2), 193–202.
4. Edvardsen, P., & Setekleiv, J. (1968). Distribution of adrenergic receptors in the urinary bladder of cats, rabbits and guinea-pigs. Acta Pharmacologica et Toxicologica, 26(5), 437–445.
5. Heisei Chozai Yakkyoku. (2013). Use of major α1-blockers and 5α-reductase inhibitors in benign prostatic hypertrophy. http://www.heisei-ph.com/pdf/H25.2.21_y.pdf . Accessed March 14, 2016.